Trial
NCT04424966
Infigratinib in Recurrent High-Grade Glioma Patients
Early Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Nader Sanai
Collaborators
Ivy Brain Tumor Center; Barrow Neurological Institute; QED Therapeutics, a BridgeBio company
Condition
Glioma
Intervention
Infigratinib
Why stopped
Study drug no longer available.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-24